Ignite Creation Date:
2024-05-05 @ 11:53 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00168857
Status:
COMPLETED
Last Update Posted:
2023-12-08
First Post:
2005-09-09
Brief Title:
A Prospective Randomised Double-blind Double-dummy Forced-titration Multicentre Parallel Group One Year Treatment Trial to Compare Telmisartan MICARDIS 80 mg Versus Losartan COZAAR 100 mg in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy AMADEO Study
Sponsor:
Boehringer Ingelheim
Organization:
Boehringer Ingelheim
Study Overview
Official Title:
A Prospective Randomised Double-blind Double-dummy Forced-titration Multicentre Parallel Group One Year Treatment Trial to Compare MICARDIS Telmisartan 80 mg Versus COZAAR Losartan 100 mg in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy AMADEO Study
Status:
COMPLETED
Status Verified Date:
2023-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A number of blood pressure lowering drugs in the class known as angiotensin receptor blockers ARB have been shown to slow the decline in kidney function of patients with type 2 diabetes high blood pressure and kidney disease Losartan COZAAR is one such drug The purpose of this research study is to determine if after one year of treatment telmisartan MICARDIS GLIOSARTAN KINZAL KINZALMONO PREDXAL PRITOR SAMERTAN TELMISARTAN 80 mg another blood pressure lowering drug from the ARB class is as effective as losartan COZAAR 100 mg in reducing the level of urinary protein indicative of improved kidney function
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None